No Access
INSIDE INDUSTRY
https://doi.org/10.1142/S0219030317000271Cited by:1 (Source: Crossref)
Abstract
ATOZET® a New Combination Treatment Option for High-Risk Patients to Lower LDL Cholesterol, is Now Approved in Singapore.
ASEAN+ Rare Disease Network Established.
Luye Medical Joins Forces with OncoCare To Expand Its Integrated Healthcare Services Platform for Their Patients.
NUS Pharmacy Team Develops Online “Calculator” to Predict Risk of Early Hospital Readmission.
The Bare Essentials: Ensuring Affordable Access to Insulin.
AstraZeneca’s CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Death and Hospitalisations for Heart Failure Versus Other Type-2 Diabetes Medicines.
Keywords:
- combination ,
- treatment ,
- LDL cholesterol ,
- ASEAN ,
- rare diseases ,
- patient support groups ,
- network ,
- impact study ,
- patients ,
- caregivers ,
- strategic partnership ,
- integrated ,
- healthcare services ,
- oncology ,
- waiting time ,
- demands ,
- online calculator ,
- hospital readmissions ,
- risk factors ,
- prevention ,
- access ,
- insulin ,
- affordable ,
- diabetes ,
- death ,
- heart failure ,
- Hospitalisations ,
- medicines
